SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

26 Zohydro ® ER New Patient Starts Zohydro ® ER Source of Business • Primary source of business for Zohydro ® ER with BeadTek ® is patients on IR hydrocodone • Physicians prefer to stay within the same molecule when switching a patient from an IR to an ER therapy or adding on an ER therapy • TRx data indicates that 50 % of Zohydro ® ER with BeadTek ® new patient starts are derived from patients on IR hydrocodone • 41 % added to IR hydrocodone, 9 % switched from IR hydrocodone. Importantly, add - on and switch patients show significantly higher adherence to therapy than new - to - market patients • Remaining 50 % of new patient starts are derived from: • Patients new to market ( 11 %) • Add - ons to non - hydrocodone IR therapy ( 11 %) • Add - ons to neuropathic pain therapies ( 12 %) • Other ( 16 %), including switch from non - hydrocodone IR / ER opioid therapy, switch from Hysingla ® ER and switch from / add to Tramadol • < 1 % of all patients new to Zohydro ® ER with BeadTek ® are switched from Hysingla ® ER and vice versa • Conversion of IR hydrocodone market is a core component of Zohydro ® ER with BeadTek ® growth strategy • 50% of Zohydro ® ER with BeadTek ® new patients starts are switched from or added on to IR hydrocodone scripts • As of December 2016, Zohydro ® ER with BeadTek ® and Hysingla ® ER accounted for only 0.4% of all hydrocodone prescriptions • Zohydro ® ER with BeadTek ® peak volume forecast represents only 0.3% of current IR hydrocodone market Zohydro ® ER with BeadTek ® Source of Business 480 ; 6% 1,144 ; 15% 97 ; 1% 66 ; 1% 703 ; 9% 1,087 ; 15% 3,946 ; 53% Continuing Mono Continuing Concomitant Reinitiated Mono Reinitiated Concom New to Market Switch Add-On